| Literature DB >> 27390674 |
Abdelaziz M Hussein1, Mohammed Ghalwash1, Khaled Magdy2, Osama A Abulseoud3.
Abstract
BACKGROUND ANDEntities:
Keywords: Ceftriaxone; Connexin 43; Epilepsy; Malondialdehyde (MDA); Pentylenetetrazole; Rats
Year: 2016 PMID: 27390674 PMCID: PMC4933683 DOI: 10.14581/jer.16002
Source DB: PubMed Journal: J Epilepsy Res ISSN: 2233-6249
Racine’s stage score in PTZ and ceftriaxone groups at different trial records
| Record | Group | |||
|---|---|---|---|---|
|
| ||||
| PTZ group (n = 8) | Ceft group (n = 8) | |||
| 1st | Median | 2.33 | 2.167 | 0.863 |
| Minimum | 2.0 | 1.0 | ||
| Maximum | 3.0 | 3.0 | ||
| 2nd | Median | 2.50 | 2.33 | 0.789 |
| Minimum | 2.0 | 1.0 | ||
| Maximum | 3.0 | 3.0 | ||
| 3rd | Median | 3.00 | 3.167 | |
| Minimum | 2.0 | 2.0 | 0.733 | |
| Maximum | 4.0 | 4.0 | ||
| 4th | Median | 3.50 | 3.33 | 0.575 |
| Minimum | 3.0 | 3.0 | ||
| Maximum | 4.0 | 4.0 | ||
| 5th | Median | 4.00 | 4.167 | 0.733 |
| Minimum | 3.0 | 3.0 | ||
| Maximum | 5.0 | 5.0 | ||
| 6th | Median | 4.167 | 3.00 | 0.022 |
| Minimum | 3.0 | 2.0 | ||
| Maximum | 5.0 | 4.0 | ||
| 7th | Median | 4.167 | 3.00 | 0.044 |
| Minimum | 3.0 | 2.0 | ||
| Maximum | 5.0 | 4.0 | ||
Data were expressed as median and minimum and maximum.
PTZ = pentylenetetrazole; Ceft = ceftriaxone.
p = Mann-Whitney’s test for comparison between 2 groups at the same time. Wilcoxon test for comparison between 2 time intervals in the same group;
Significant vs. 1st record of the same time group (p ≤ 0.041);
Significant vs. PTZ group of the same time period (p ≤ 0.041).
Latency of PTZ-induced seizure (sec) and duration of PTZ-induced seizure (sec) in PTZ and ceftriaxone groups in different trial records
| Record Group | 1st | 2nd | 3rd | 4th | 5th | 6th | 7th | |
|---|---|---|---|---|---|---|---|---|
| Latency of Seizure (sec) | ||||||||
| PTZ group (n = 8) | 327.0 ± 28.50 | 174.0 ± 49.04 | 75.70 ± 12.50 | 56.20 ± 11.00 | 25.20 ± 10.43 | 23.11 ± 9.80 | 24.70 ± 8.60 | |
| Ceft- group (n = 8) | 319.01 ± 35.05 | 182.0 ± 38.60 | 89.20 ± 15.45 | 49.70 ± 14.30 | 29.10 ± 8.15 | 110.50 ± 25.90 | 129.06 ± 15.60 | |
| Duration of Seizure (sec) | ||||||||
| PTZ group (n = 8) | 4.10 ± 0.63 | 21.40 ± 1.95 | 104.50 ± 39.10 | 165.0 ± 28.80 | 185.50 ± 33.50 | 211.50 ± 29.70 | 218.50 ± 25.40 | |
| Ceft- group (n = 8) | 5.10 ± 0.95 | 29.0 ± 7.80 | 124.0 ± 28.60 | 159.50 ± 42.50 | 178.60 ± 26.80 | 115.50 ± 25.70 | 101.50 ± 11.30 |
Data expressed as mean ± SD. Independent T test for comparisons between 2 groups of the same time and paired T test for comparison between 2 trials of the same group.
PTZ, pentylenetetrazole; Ceft, ceftriaxone.
Significant vs. 1st trial;
Significant vs. 4th trial;
Significant vs. 5th trial;
Significant vs. 2nd trial;
Significant vs. 3rd trial;
Significant vs. PTZ group of the same time period.
Figure 1.Markers of oxidative stress in hippocamal regions of rat’s brain in different groups. Malondialdehyde (MDA) (nmol/g brain tissues) (A), reduced glutathione (GSH) concentration mmol/g brain tissue (B) and catalase activity (U/g brain tissues) (C). Ceft, ceftriaxone. *Significant vs. normal group (p < 0.01); †Significant vs. pentylenetetrazole (PTZ) group (p < 0.05).
Figure 2.Mean area of interest of Cx43 positivity in CA3 region of hippocampus from different groups (A). Section of brain in CA3 region of hippocampus showing negative expression for Cx43 (normal group) (B). High membranous brown staining for Cx43 (arrows) (pentylenetetrazole [PTZ] group) (C, D) and negative expression for Cx43 (Ceft-group) (E) (400×). Ceft, ceftriaxone. *Significant vs. normal group (p < 0.01); †Significant vs. PTZ group (p < 0.05).